ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

New Biologic Modalities Show Promise In Treatment Of Lymphomas, Research Finds

June 28, 2002

FDA Proposes New User Fees for Generics and Biosimilar Products

January 20, 2012

M.D. Anderson Investigator Gave Drug To Patients Without IND; NCI Probes Incident, To Make Report

July 17, 1981

BMS Control Of Billion-Dollar Taxol Market Facing Court Challeges By Competitors

May 29, 1998

Funding Opportunity: DOD Offering 10.5 Million For Lung Cancer Research

May 30, 2014

CPRIT Awards $107.2 Million Round of Grants

September 5, 2014